Truncated glycoprotein G of herpes simplex virus 2
AssigneeSimplexia AB
InventorJan-Åke Liljeqvist
Life of this patent
Estimating the term…
Loading patent…
AssigneeSimplexia AB
InventorJan-Åke Liljeqvist
Estimating the term…
The present invention relates to a protein comprising a truncated version of the HSV-2 protein mg G-2, said protein comprising: (i) an extracellular region of mg G-2 (EX-mg G-2), or a truncated version thereof, of at least 285 amino acids; said extracellular region or truncated version thereof having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 3; (ii) a truncated transmembrane region of mg G-2 (t-TMR-mg G-2) of 2 to 15 amino acids; said truncated transmembrane region having at least 90% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 6; and (iii) an intracellular region of mg G-2 (IC-mg G-2), or a truncated version thereof, of at least 18 amino acids; said intracellular region or truncated version thereof having at least 90% or 95% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 8.
A protein comprising a truncated version of the herpes simplex virus 2 (HSV-2) protein membrane-bound glycoprotein G (mgG-2), said protein comprising:
A protein EXCT4-mgG-2, having an amino acid sequence as defined in SEQ ID NO:
An HSV-2 vaccine comprising the protein EXCT4-mgG-2, wherein said protein EXCT4-mgG-2 has an amino acid sequence as defined in SEQ ID NO:5.
Dependencies are inferred from the claim text.